The past 12 months or so have seen Calliditas Therapeutics AB attract a Chinese partner, start a Phase III study of its lead product, and conduct a follow-on financing to its June 2018 IPO. All of this has improved business options for the Swedish biotech and, in particular, “the capital has given us flexibility,” noted Calliditas’s CEO, Renée Aguiar-Lucander.
Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate
A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.
More from Immunological
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.